Iatrogenic Alterations of Immunologic Surveillance in Man and Their Influence on Malignancy by Starzl, TE et al.
Transplant. Rev. (1971), Vol. 7 112-145 
Published by Munksgaard, Copenhagen, Denmark 
No part may be reproduced by any process without written permission from the author(s) 
Iatrogenic Alterations of 
Immunologic Surveillance in Man and 
Their Influence on Malignancy 
T. E. STARZL, I. PENN, C. W. PUTNAM, C. G. GROTH & C. G. HALGRIMSON 
The surveillance hypothesis of the immunologic control of malignancy has 
far-reaching clinical implications, of which two major and essentially op-
posite ones will be considered in this communication. The first concerns 
the growth of tumors in patients with surveillance failure. From the prem-
ise of Burnet (1957, 1963, 1967, 1970) and Thomas (1959), it could have 
been predicted and was (Thomas 1959, Starzl 1964b, Schwartz et al. 1966) 
that an increased incidence of de novo tumors would develop in people with 
naturally occurring immunologic deficiency diseases or in patients whose 
immune reactivity was deliberately depressed in order to permit their ac-
ceptance of organ homografts. The hazard of malignancy consequent to 
spontaneous deficiency is so well known (Page et al. 1963, Green et al. 
1966, Dent et al. 1968, Huber 1968) that it will not be reviewed here. 
However, the analogous data in iatrogenically immunosuppressed transplant 
recipients that have accumulated since 1968 will be brought up to date. 
In addition, some comments will be made about the accidental transplan-
tation of tumors to immunologically depressed humans and about the growth 
of metastases or residual tumor under these same conditions. 
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The second general topic of this report, and a far more interesting one 
from a therapeutic point of view, is the expectation that the artificial en-
dowment of immunologic surveillance in a patient whose natural defense 
system had failed to prevent neoplasia might then have an inhibitory or 
even destructive effect upon the established growth. Of course, a necessary 
condition to evaluate this latter possibility is the successful transplantation 
of immunologically competent tissue such as spleen or bone marrow while 
at the same time avoiding the kind of fatal graft-versus-host reaction that 
has defeated essentially all efforts at bone marrow grafting for whatever 
purpose except between a few HL-A identical siblings. As a first step to-
ward this previously unattainable goal, suggestions will be made for the 
application to the bone marrow problem of immunosuppressive regimens 
that have been evolved in the successful transplantation of whole organs 
such as the kidney, liver, and heart. 
IMMUNOSUPPRESSION AND DE NOVO MALIGNANCIES 
Although it was hardly surprising when it occurred, a convincing association 
between immunosuppression and new malignant neoplasms was not claimed 
until European and American meetings held respectively in March and 
April 1968 (Starzl et al. 1969, Starzl 1968). Prior to the first of these 
conferences, two reticulum cell sarcomas had been observed in our own 
patients and an anaplastic neoplasm (later judged to be a carcinoma) had 
been contributed to us by Dr. Claude Hitchcock of Minneapolis; in dis-
cussion of the paper from the floor, Woodruff added another reticulum cell 
sarcoma from his Edinburgh experience. By the time of the second meeting 
in Boston less than a month later, a third lymphoma had been encountered 
in our series. The five cases were discussed again at a Dundee, Scotland, 
cancer symposium on 31 May, 1968, and as a consequence were reported 
in an Annotation in The Lancet (1968). 
When the subject was covered again the following September at the 
International Transplantation (Penn et al. 1969) and Sixth National Can-
cer (Starzl et at. 1970c) meetings, additional examples of both mesenchymal 
and epithelial malignancy were added from our own institution or were 
mentioned by interested audience members making the case total up to 13 
(McKhann 1969). Since then, an unofficial registry of de novo malignancies 
has been kept in Denver to which observations have been fed in from all 
over the world and summarized on several occasions (Penn et aT. 1969, 
1971, Penn 1970, Penn & Starzl 1970, Starzl et al. 1970b). The following 
remarks will be based partly upon this donated material, partly upon the 
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TABLE 
De novo malignancies in kidney transplant 
Age at Immunosuppression 
time of 
No. transplan-
tation Sex Donor I SpIe- I Thy- I Aza- I Pred- I ALG 
nectomy mectomy thioprine nisone 
37 F Unrelated Yes Yes Yes Yes No 
living donor 
2 40 M Unrelated Yes No Yes Yes No 
living donor 
3 39 M Brother Yes Yes Yes Yes No 
4 40 M Unrelated Yes Yes Yes Yes No 
living donor 
5 43 M Uncle Yes No Yes Yes Yes 
6 30 M Brother Yes Yes Yes Yes No 
7 34 M Sister Yes No Yes Yes No 
8 44 F Sister Yes No Yes Yes Yes 
9 22 M Cousin Yes No Yes Yes No 
10 26 F Father Yes No Yes Yes No 
11 17 F Father Yes No Yes Yes Yes 
12 30 M Brother Yes No Yes Yes Yes 
13 14 M Mother Yes No Yes Yes Yes 
14 23 M Father Yes Yes Yes Yes No 
15 20 F Father Yes No Yes Yes Yes 
published reports of some of these cases from other institutions (Doak 
et al. 1968, Zukoski et al. 1968, Deodhar et at. 1969, Siegel et al. 1969, 
Kay et al. 1970, Pritzker et al. 1970, Simmons et al. 1970, Tallent et al. 
1971, Walker et al. 1971) but principally upon the study of patients in our 
own transplantation program. 
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I 
recipients at the University of Colorado 
Type of tumor 
Squamous cell carcinoma 
in situ 
Superficial squamous cell 
carcinoma 
Superficial squamous cell 
carcinoma 
Squamous cell carcinoma 
Basal cell carcinoma 
Basal cell carcinoma 
Squamous cell carcinoma 
Moderately differentiated 
adenocarcinoma 
Squamous cell carcinoma 
Squamous cell carcinoma 
in situ 
Squamous cell carcinoma 
in situ 
Superficial squamous cell 
carcinoma 
Reticulum cell sarcoma 
Reticulum cell sarcoma 
Unclassified lymphoma 
Time after 
trans-
plantation 
(months) 
50 
66 
36 
32 
33 
75 
74 
31 
78 
65 
51 
36 
5Y2 
30 
7 
Organs involved 
Cervix of uterus 
Lower lip 
Lower lip 
Skin of ear 
Nasolabial fold 
Nasolabial fold 
Both forearms, 
right arm, scalp 
Lung 
Left hand 
Cervix of uterus 
Cervix of uterus 
Face (3 areas) 
Brain 
Thyroid, liver, lung, 
stomach, prostate, 
pituitary, skin, psoas 
muscle 
Brain 
University of Colorado Series 
Outcome 
Alive, no recurrence after 
hysterectomy 
Alive, no recurrence fol-
lowing excision 
Alive, no recurrence fol-
lowing excision 
No recurrence after exci-
sion, died of other causes 
Alive, no recurrence fol-
lowing excision 
Alive, no recurrence fol-
lowing excision 
No recurrence after exci-
sion, died of other causes 
Cancer was incidental 
finding at autopsy 
Alive, no recurrence fol-
lowing excision 
Alive, no recurrence fol-
lowing excision 
Alive, no recurrence fol-
lowing excision 
Alive, no recurrence fol-
lowing excision 
Died of tumor 
Died of tumor 
Alive, no recurrence fol-
lowing radiotherapy 
It will be useful to record our own experience with post-transplantation 
neoplasia separately from that collected on a cooperative basis from else-
where. For one thing, an accurate idea of the true incidence and severity 
of the problem cannot be obtained from the world experience, since neither 
8* 
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TABLE II 
University of Colorado, de novo malignancies 
Total number of patients 
Related donor 
Non-related donor, living 
Non-related donor, cadaver 
Patients with malignancies 
Related donor 
Non-related donor 
I 
195 
15 
Number of patients surviving more than 4 months 
Incidence of malignancy 
In all patients 
In patients surviving more than 4 months 
141 
35 
19 
12 
3 
154 
Group 
7.7 % 
9.7 % 
111 
II 
90 
0 
21 
0 
0 
0 
92 
0% 
0% 
the exact number of malignancies nor the numbers of patients at risk at 
various postoperative times are known. Moreover, there has been an ob-
vious great variability in therapy from center to center, and it has not been 
easy to assess accurately or even to know about all the details of treat-
ment. These limitations do not apply to our own series of patients (Table I). 
Case Material and Immunosuppression. Our experience has been sub-
divided into two fractions according to whether the potential foHow-up was 
greater or less than 3 years. Group I consisted of 195 consecutive recipients 
who were given renal homografts between November 1962 and 1 July 1968 
(3 to 8 2fa years ago). Group II comprised 111 patients treated between 
1 July 1968 and 1 January 1971 (6 months to 3 years ago). 
The patients in Group I treated 5 years or longer ago had immunosup-
pression with a double drug program of azathioprine and prednisone (Starzl 
1964b). All patients treated since June 1966, including the last members 
of Group I as well as all the recipients in Group II had horse ALG added 
as a third agent in what has been termed the triple drug regimen (Starz! 
1969). Splenectomy was carried out in more; than 90 per cent of cases of 
both groups, being omitted only in some of the cadaveric transplantations. 
Thymectomy was carried out in 36 patients of Group I prior to transplan-
tation and at some time during the first year after transplantation in an 
additional 9 (Starz! et aT. 1970b). 
Incidence of Malignancy. Fifteen of the 195 consecutive recipients in 
---------------- -
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TABLE III 
De novo malignancies at University of Colorado and in collected series 
University All 
of Colorado other Total 
Average age of patient (years) 30.6 33.0 32.3 
Average time of appearance of tumor 
(months after transplantation) 44.6 25.0 30.1 
Splenectomy 15/15 8/42 23/57 
Thymectomy 5/15 0/42 5/51 
ALG treatment 6/15 10/42 16/57 
Group I developed malignant tumors for an uncorrected incidence of 7.7 
per cent (Table II). The incidence of the cQmplicatiQn was approximately the 
same after unrelated (3/54) as opPQsed too related transplantation (121141). 
Since 41 Qf the 195 patients of GrQup I died in less than 4 months, 
befQre they were exposed to a significant hazard of neoplasia, the actual 
number at risk was Qnly 154. Within this culled series, the corrected in-
cidence (151154) was an extraO'rdinary 9.7 per cent (Table II). Taken un-
critically, this figure could be interpreted as being sO' high as too virtually 
cancel the usefulness of organ transplantatiQn. However, as will be men-
tiooned later, the majority of the tumors were easily treated. Only 2 Qf the 
patients died from the malignancy, both with reticulum cell sarCQma (Table 
I, Cases 13 and 14). 
MO'reQver, nQt a single additiQnal example of de novo malignancy has 
been encQuntered in the moore recently treated 111 patients of GrQup II 
(Table II). If all the cases of Groups I and II are combined, the uncoorrected 
incidence of malignant neoplasia is 4.9 per cent and excluding patients who 
died in the first 4 moonths, it corrects to 6.1 per cent. 
The rate of tumQr develQpment in our combined series of generally young 
transplantation patients EP~ too 50 years, average approximately 28 years) 
coompares with a yearly incidence of 58 per 100,000 (0.058 per cent) in 
a general East Cooast population* of a comparable age range (Doll et al. 
1966). In the foregoing state-wide statistics, carcinomas in situ were ex-
cluded. In our transplant series 3 of the 15 malignancies were of this kind. 
Omitting these, the incidence of malignant disease in the 306 patients of 
the combined Groups I and II is 3.9 per cent. 
The Timing of the Malignancies. As already mentioned, all 15 cases of 
* Cancer Registry, State of Connecticut, 1960 to 1962. The statistics from New York 
are essentially the same. 
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de /laVa malignancy occurred in the patients of Group I. The diagnoses 
were made (Tables I and III) from 51/2 to 78 months after transplantation 
(average 44,6 months) when the patients were 15 to 47 years old (average 
34.4). Only 2 malignancies were identified within the first year (Cases 13 
and 15), 6 more occurred in the second and third years (Cases 3-5, 8, 12 
and 14), and the other 7 developed after from 50 to 78 months. The 3 
most serious neoplasms, 2 reticulum cell sarcomas (Cases 13 and 14) and 
one lymphoma of unclassified type (Case 15), were the earliest to appear, 
after 51f2, 30 and 7 months, respectively. 
There has been no obvious explanation for the curious absence of ad-
ditional de 1l0VO tumors in the Group II patients treated by transplantation 
under triple drug immunosuppression since July 1968. 
Tumor Types and Organs Affected. In our original reports, the main 
attention was directed to the lymphorelicular neoplasms of which there 
were three. Three years later, there have been no new examples of such 
mesenchymal tumors which now constitute only 20 per cent of the case 
total. The other 12 patients (80 per cent) have had carcinomas (Table I) 
affecting in 11 instances the squamous epithelium of the lip, uterine cervix, 
and skin (especially that of the face and hand). Multiple primary skin can-
cers were found in two of these cases. The twelfth patient with an epithelial 
Figure 1. Disseminated reticulum cell sarcoma in a renal homograft recipient in OUf 
series (Table I, Case 14). A: This 5 cm nodule was one of several found in the liver. 
B: Malignant reticulum cells have massively infiltrated the thyroid, sepa.rating the 
follicles widely (x 80). (By permission of Trallsp/anl. Proc. 1, 106, 1969.) 
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malignancy (Case 8) died of other causes and was found at autopsy to have 
a small adenocarcinoma of the lung. 
Disseminated tumor (Figure 1) was found only in an organ recipient 
who had reticulum cell sarcoma in the brain, liver, lung, and five other lo-
cations (Table I, Case 14). The other reticulum cell sarcoma (Case 13) 
and an unclassified lymphoma (Case 15) also involved the brain (Figure 2) 
but were confined to this organ. 
Malignancies versus Immunosuppression. In experimental animals each 
of the main immunosuppressive agents, azathioprine (Casey 1968), pred-
nisone (Foley & Silverstein 1951 , Agosin eL al. 1952, Toolan 1953, Baserga 
& Shubik 1954, Albert & Ziedman 1962), and ALG (Anigsten eL al. 1966, 
Allison eL al. 1967, Bremberg eL al. 1967, Davis & Lewis 1967, Deodhar 
eL ai. 1968, Hellman eL al. 1968, Hirsch & Murphy 1968, Fisher eL ai. 1969, 
Mandel & DeCosse 1969, Vredevoe & Hays 1969, Rabbat & Jeejeebhoy 
1970) has been shown in animals either to (1) increase the incidence of 
Figure 2. Case 15 in Colorado series (see Table l). Tumor nodules (arrows) in the 
left occipital lobe and cerebellum . The flattened gyri reflect increased intracranial 
pressure caused by the tumor. Insert - the large uniform cells with indistinct cyto-
plasm and round to oval nuclei are characteristic of reticulum cell sarcoma (x 350). 
(By permission of Transpianl. Proc. 1, 106, 1969.) 
120 STARZL, PENN, PUTNAM, GROTH & HALGRIMSON 
spontaneous, virus-induced, or chemically initiated tumors; (2) facilitate the 
ease with which malignant cells can be transplanted; or (3) accelerate meta-
static growth. All of our patients received two of the aforementioned three 
agents, namely azathioprine and prednisone. On the other hand, the first 
110 recipients were not given horse ALG, whereas the subsequent 196 
were also administered the equine globulin. Although almost two-thirds of 
the patients thus were treated with the triple drug schedule, only 6 of the 
15 de novo malignancies developed under these conditions, including one 
fatal reticulum cell sarcoma. The other 9 tumors, including the other lethal 
reticulum cell sarcoma were distributed throughout the minority of recipients 
who were given only azathioprine and prednisone. 
On the basis of these data, it is clear that ALG has not made a unique 
contribution to the complication of post-transplantation neoplasia. If any-
thing, the problem has actually seemed less since the introduction of ALG, 
something which might have been expected if, as has been described (Starzl 
et al. 1967, Starzl 1969), globulin therapy permitted better control of rejec-
tion along with reduction in the quantities of the other two agents required 
for chronic maintenance. In view of these findings, it is difficult to under-
stand the origin of the widespread misconception that the incidence of tu-
mors in the posttransplantation period has increased since the use of ALG. 
Thymectomy (Martinez et al. 1962, Vandeputte et al. 1963, Miller et al. 
1964, Grant & Miller 1965, Allison et al. 1967, Davis & Lewis 1967, Law 
1969) has also been shown in animals to promote tumor growth. Amongst 
the first 110 consecutive transplant patients treated at the University of 
Colorado, there were 45 whose thymus gland was excised. Five cases of 
de novo malignancies came from this special subpopulation, including a 
fatal reticulum cell sarcoma. However, there were four malignancies in-
cluding the other lethal reticulum cell sarcoma in the 65 non-thymectomized 
recipients who were treated with transplantation during the same era of 
our experience. An authoritative opinion about the role of thymectomy in 
causing this complication in humans cannot be given, since the differences 
in incidence are not statistically significant. 
Splenectomy as a factor in O'ncogenesis could not be studied from our 
experience since there were toO' small a number O'f non-splenectomy controls. 
Treatment and Prognosis. Both of the patients with reticulum cell sarcoma 
died. In Case 14, the diagnosis was not made until autopsy. The other 
patient (Case 13) died a few days after craniotomy and biopsy. 
The diagnosis in the recipient with an unclassified lymphoma was made 
by biopsy of the diencephalic lesion (Figure 3) with a stereotaxic instrument. 
The tumor was then irradiated with 5,650 rads. In addition, immunosup-
pressive therapy was lightened, despite which renal graft rejection did not 
IMMUNOLOGIC SURVEILLANCE INFLUENCE ON MALIGNANCY 121 
follow (Figure 4) . Except for some residual neurological impairment. she 
is well three years later, still with function of her transplanted kidney. 
Three patients with epithelia] tumors also died, but from complications 
of uremia or vascular disease rather than from cancer. Two of these three 
recipients had squamous cell carcinomas of the skin (Cases 4 and 7) that 
Figure 3. Pneumoencephalogram in a 20-year-old woman who had been treated 
with renal homotransplantation a few months previously . Progressive hemiparesis had 
developed postoperatively. A mass was found, protruding into the right lateral ven-
tricle. This was biopsied with stereotaxic apparatus and found to be a plasmacytoma. 
(By permission of Radiology 95, 1, 1970.) 
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were completely excised. The third patient (Case 8) was the one with an 
incidental carcinoma of the lung found at autopsy. 
The other nine recipients with de novo epithelial malignancies were all 
successfully treated by standard and relatively conservative excisions. With 
follow-ups of 1 month to 2 years there have been no recurrences. 
Cases from Other Transplantation Centers 
Data concerning additional de novo malignancies in one cardiac and 41 
renal homograft recipients have been collected from transplantation centers 
throughout the world. These are summarized in Table IV. As in the Co-
lorado series, the patients tended to be young (age range 8 to 58 years, 
average 33 years) and all had received immunosuppression with azathio-
prine and prednisone. 
However, there were some quantitative differences between the local and 
collected series. For example, 21 of the contributed 42 cases (50 per cent) 
had some type of mesenchymal tumor, of which the most common by far 
was reticulum cell sarcoma, whereas mesenchymal malignancies accounted 
for only 3 of 15 of the Colorado cases (20 per cent). The disparity prob-
WBC 
Cor 
(ml/min.) 
BUN 
(mg per 100 ml) 
AZATHIOPRINE 
(mg) 
PREDNISONE 
(mg) 
ALG 
LD 152 
TUMOR 
IRRADIATION 
9 10 20 40 60 60 100 120 140 160 160 200 220 240 260 260 300 320 340 360 
RENAL TRANSPLANTATION 
TIME IN DAYS 
Figure 4. The clinical course of the patient whose pneumoencephalogram is shown 
in Figure 3. When the diencephalic tumor was diagnosed, immunosuppression was 
drastically reduced, and the intracranial neoplasm was irradiated with a total of 
5,650 R. Kidney function was well maintained, and tumor growth is apparently ar-
rested since the patient has been well for more than three subsequent years. (By per-
mission of Transplant. Proc. 1, 106, 1969.) 
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ably represents a reporting artifact in that there would be a tendency to 
report only the more florid and lethal malignancies to the registry with the 
dismissal of many skin tumors or in situ carcinomas of the cervix as rel-
atively unimportant. 
As in our own cases, highly malignant tumors have tended to' occur much 
earlier after transplantation than the relatively low grade lesions of skin, 
lip, and uterine cervix. CQnsequently, the average time Qf appearance of 
the tumor after transplantation in the 42 cases from other institutions was 
only 25 months as compared with 44.6 months in the ColoradO' series. The 
higher proPQrtion of exceptionally malignant tumors alsO' accQunted for the 
relatively poor prognosis in the collected cases, only 12 Qf the 42 patients 
surviving at the time of reporting as compared with a 10 Qf 15 current 
survival in our own patients. 
Other differences between the Colorado and the world series reflect pri-
marily variations in management from institution to institution (Table III). 
Splenectomy was performed in all of our malignancy cases but in only 8 
of 42 from elsewhere. The thymus gland had been removed from 5 of the 
15 Colorado patients but nQt from any in the world series. ALG was given 
in 6 of 15 (40 per cent) of our cases and in Qnly 10 of 42 (24 per cent) 
from other centers. 
An unusual feature of thc lymphomas both in the CQlorado and the 
world series was the frequency with which the brain was involved. Of a 
total of 22 lymphomas (reticulum cell, KapO'si's, and unclassified) in the 
combined series, the brain was involved in 11, and was the only Qrgan 
affected in 8 of these patients (Schneck & Penn 1971). 
IMMUNOSUPPRESSION AND THE ACCIDENTAL TRANSPLANTATION 
OF TUMORS 
It was Qriginally proposed by Burnet (1957) that the individuality of tumor 
cells, which allows their recQgnition as foreign, might be due to' tumQr-
specific (T) antigens (Foley 1933, Gorer 1937, Prehn & Main 1957, Old 
& Boyse 1964, SQutham 1964, Klein 1966, Isojima et at. 1969, Law 1969) 
not found in the nQrmal host tissues. Such extra antigens are probably 
present on mQst if not all malignant cells but they are thought to be so 
weak that a surveillance mechanism that could detect them as 'non-self' 
must have exquisite discrimination. The presumed disruptiQn of such a 
refined biologic apparatus by immunosuppression as an explanation for the 
de novo malignancies observed after transplantation is not difficult to en-
vision. 
No. 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
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Transplant Age at time 
of trans- Sex Donor Center plantation 
Edinburgh, 26 F Mother 
Scotland 
Cleveland 32 M Cadaver 
Richmond 38 M Cadaver 
Auckland, 34 M a) Cadaver 
New Zealand b) Cadaver 
c) Cadaver 
Auckland, 46 F Cadaver 
New Zealand 
New York 18 M Uncle 
New York 36 M Cadaver 
Richmond 29 M Brother 
Little Rock, 21 M Father 
Arkansas 
San Francisco 39 F Sister 
Richmond 18 M Father 
New York 35 F Cadaver 
Boston 34 M a) Cadaver 
b) Half-sister 
Montreal 36 M Cadaver 
Israel 28 M Cadaver 
Israel 38 F Cadaver 
Oklahoma City 19 F Cadaver 
Chapel Hill * 39 M Cadaver 
Los Angeles 23 M Cadaver 
Chicago 52 M Cadaver 
San Francisco 24 M 1) Brother 
2) Cadaver 
3) Cadaver 
4) Cadaver 
Minneapolis 28 F Brother 
Splenec-
tomy 
No 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
TABLE 
De novo malignancies in organ 
Imm unosuppression 
IThymec-1 Aza~hio-f -\red-
tomy pnne msone IALG 
No Yes Yes Yes 
No Yes Yes Yes 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
No Yes Yes Yes 
No Yes Yes N0 
No Yes Yes No 
No Yes Yes No 
No Yes Yes No 
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IV 
transplant recipients at other centers 
~ I:l.-~ ,.9.c Contributing Type of tumor ~~~b Organs involved Outcome S .... ~ 0 physician K~ ... ~ S 
f-' 0.'-" 
Reticulum cell sarcoma 25 Lymph nodes, pleura, 
spleen, liver, ovary, adre-
nal, bone marrow, and 
transplanted kidney Dead Prof. M. VVoodruff 
Reticulum cell sarcoma 22 Buttock, lungs, aortic 
lymph nodes Dead Dr. S. D. Deodhar 
Reticulum cell sarcoma 31 Lung, aortic lymph nodes Dead Dr. J. Pierce 
Reticulum cell sarcoma 7 Tongue, esophagus, liver Dead Dr. P. Doak 
Reticulum cell sarcoma 9 Brain Dead Dr. P. Doak 
Reticulum cell sarcoma 9 Brain Dead Dr. R. Porro 
Reticulum cell sarcoma 10 Brain Dead Dr. F. Veith 
Reticulum cell sarcoma 67 VVidespread lymph nodes, 
liver, vertebrae Dead Dr.H. Lee 
Reticulum cell sarcoma 24 Brain Dead Dr. C. Araoz 
Reticulum cell sarcoma 14 Brain, lungs Dead Dr. F. O. Belzer 
Reticulum cell sarcoma 73 VVidespread lymph nodes, 
liver, pancreas, bone mar-
row, meninges, bladder, 
testes, transplanted kidney, 
accessory spleen, sciatic 
nerve, lung Dead Dr.H.M. Lee 
Visceral Kaposi's 10 Lungs, esophagus, stomach, 
sarcoma urinary bladder, media-
stinal and abdominal lymph 
nodes Dead Dr. 1. H. Siegel 
Leiomyosarcoma 47 Stomach, perigastric lymph 
node, peritoneum, bowel, 
liver, lungs, vertebrae and 
ribs Dead Dr. R. E. VVilson 
Leiomyosarcoma 51 Small bowel, liver, pan-
creas Dead Dr. L. D. MacLean 
Kaposi's sarcoma 9 Skin, mucosa of mouth Alive Dr. B. Myers 
a) Reticulum cell 9 a) Brain 
sarcoma b) Skin Alive Dr. B. Myers 
b) Kaposi's sarcoma 
Reticulum cell sarcoma 13 Lungs, liver, spleen, rec-
tum, transplanted kidney, 
mesentery, bone marrow Dead Dr. Y. Muto 
Synovial sarcoma 12 Right popliteal fossa, lungs, 
liver, small bowel Dead Dr. VV. B. Blythe 
Unclassified lymphoma 46 Brain Dead Dr. R. Goldman 
Reticulum cell sarcoma 7'h Brain Dead Dr. N. Levine 
Reticulum cell sarcoma 41 Brain, cervical lymph nodes Dead Dr. F. O. Belzer 
Squamous cell 30 Cervix of uterus Alive, no recurrence Dr. R. L. Simmons 
carcinoma in situ after hysterectomy (cont.) 
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TABLE IV (cont.) 
Transplant Age at time 
Immunosuppression 
No. of trans- Sex Donor Center plantation Splenec- iThymec-i Aza~hio-f ~red-
i ALG tomy tomy pnne msone 
23 Montreal 38 F Cadaver No No Yes Yes Yes 
24 Los Angeles 38 F Mother No No Yes Yes No 
25 Richmond 33 F Sister No No Yes Yes No 
26 Louisville 35 M Brother No No Yes Yes No 
27 Los Angeles 27 M Mother No No Yes Yes No 
28 Los Angeles 25 F Brother No No Yes Yes No 
29 Minneapolis 27 M Brother Yes No Yes Yes No 
30 Nashville 47 M Cadaver No No Yes Yes No 
31 San Francisco 46 M a) Son Yes No Yes Yes No 
b) Cadaver 
32 Minneapolis 16 F Cadaver No No Yes Yes No 
33 Ghent, Belgium 53 F Cadaver No No Yes Yes No 
34 Nashville 34 M Cadaver No No Yes Yes No 
35 Louisville 32 M Brother Yes No Yes Yes No 
36 Cape Town** 50 M Cadaver No No Yes Yes Yes 
37 Stockholm, 58 M Cadaver No No Yes Yes No 
Sweden 
38 Salt Lake City 42 M Cadaver No No Yes Yes Yes 
39 Sydney, 48 F Cadaver No No Yes Yes No 
Australia 
40 Toronto*** 21 M Cadaver No No Yes Yes Yes 
41 Montreal 13 M Brother No No Yes Yes No 
42 Toronto 8 F Cadaver No No Yes Yes Yes 
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Type of tumor 
--------, 
Squamous cell 
carcinoma in situ 
Squamous cel! 
carcinoma in situ 
Squamous cel! 
carcinoma in situ 
Squamous cell 
carcinoma 
Squamous cell 
carcinoma 
Squamous cell 
carcinoma 
Undifferentiated 
carcinoma 
Undifferentiated 
carcinoma 
Alveolar cell carcinoma 
of lung 
Dysgerminoma 
Adenocarcinoma 
Squamous cel! 
carcinoma 
Embryonal cell 
carcinoma 
Anaplastic small cell 
adenocarcinoma 
Multiple squamous 
cell carcinomas 
Squamous cell 
carcinoma 
Squamous cell 
carcinoma 
Highly anaplastic 
transitional cell tumor 
Hepatocell ular 
carcinoma 
Well differentiated 
hepatoma 
E §~ 
~ ~K:§ ~ Organs involved 
S .... ~ 0 f=~~R 
6 Cervix of uterus 
35 Cervix of uterus, anterior 
wall of vagina 
36 Cervix of uterus 
8 Lower lip 
25 Lower lip 
35 Lower lip 
10 Liver, brain, bone marrow 
19 Lung, mediastinal lymph 
nodes, brain, liver 
9 Lungs 
32 Ovary, peritoneum, media-
stinal and axillary lymph 
nodes 
35 Sigmoid colon, liver 
62 Metastases in lymph nodes 
of neck, later widespread 
metastases. Primary site of 
tumor unknown 
2 Testis, abdominal organs, 
ureter of transplanted kid-
ney, lung 
17 Stomach, liver. mesentery, 
peritoneum 
38 Scalp 
32 Lip 
29 Right forehead, right naso-
labial fold 
6 Kidney, liver, brain, heart, 
lung 
32 Liver 
13 Liver 
Outcome 
Alive, no recurrence 
after cryosurgery 
Alive, no recurrence 
after excision 
Cone biopsy, patient 
being observed at 
regular intervals 
Alive, no recurrence 
following excision 
Alive, no recurrence 
following excision 
Alive, no recurrence 
following excision 
Dead 
Dead 
Dead 
Dead 
Dead 
Dead 
Dead 
Dead 
Alive 
Alive 
Alive 
Dead 
Dead 
Dead 
* Tumor appeared after immunosuppression was discontinued. 
** Heart transplant recipient. 
*** Tumor may have been present at the time of transplantation. 
Contributing 
physician 
Dr. K. Pritzker 
Dr. A. Gordon 
Dr. H. Lee 
Dr. D. Leb 
Dr. R. Goldman 
Dr. R. Goldman 
Dr. C. Hitchcock 
Dr. C. Zukoski 
Dr. S. Kountz 
Dr. W. Kelly 
Dr. F. Derom 
Dr. C. Zukoski 
Dr. D. Leb 
Dr. S. Bosman 
C. Franksson 
Dr. L. Stevens 
Dr. J. H. Stuart 
Dr. G. DeVeber 
Dr. K. Pritzker 
Dr. A. Millner 
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With the transplantation of tumor homografts, the task of surveillance 
in a normal person should by no means be as subtle. Under this> circum-
stance, T antigen(s) in the neoplastic tissue may help t01 elicit an immune 
reaction from a recipient but probably only to a very minor degree. The 
principal response as> with any homograft is determined by histocompatibility 
differences between the donor and recipient. Since the vigor of homologous 
tumor rejection is thus governed in a general way by the same rules of histo-
compatibility to which normal tissues are subject (Jensen 1922, Gorer 1937, 
Snell 1952, Old & Boyse 1964, Sjogren 1965, Burnet 1967, Mogensen & 
Kissmeyer-Nielsen 1968, Law 1969), the repudiation of a transplanted neo~ 
plasm should be preventable by any treatment which is protective for other 
kinds of homografts. 
This major point has been confirmed clinically by a small but revealing 
series of observations. A few years ago, several different transplantation 
teams employed renal hom01grafts that had been obtained from cadaveric 
donors whose deaths were caused by carcinomas of the lung (Martin et al. 
1965, Wilson et ai. 1968), pyriform sinus (McIntosh et aI. 1965), thyroid 
(Muizniks et at. 1968), breast (MacLean et at. 1965), or liver (Zukoski 
et at. 1970). In each instance the kidney was not thought to have been 
involved by tumor at the time of its excision. However, in two instances the 
homografts were removed within a few days after their transplantation and 
were found to contain microscopic metastases (MacLean et at. 1965, Muiz-
niks et at. 1968). These observations were of interest since they showed 
how easily cancer cells could inadvertently be transferred under these dan-
gerous conditions. The patients did not subsequently develop metastases. 
However, the potentially tragic consequences of the practice of accepting 
cancer victims as donors soon became apparent in the four other patients 
who had the misfortune to achieve good initial renal function from their 
grafts and who, thcrefore, were placed on chronic immunosuppression. Four 
to 36 months later, malignancies of the same histologic type as that causing 
the death of the donor were found in the transplanted organs. In two of 
the four recipients, the tumor had already' become autonomous in that it 
continued to flourish and caused fatal metastases even though immunosup-
pression was stopped and the renal portion of the composite graft was re-
jected (Martin et aI. 1965, McIntosh et al. 1965). The local or distant meta-
stases in the other two patients underwent involution and final complete 
disappearance after discontinuance of immunosuppression and loss of the 
renal homografts (Wilson et ai. 1968, Zukoski et aI. 1970). The spread in 
Zukoski's remarkable case was very extensive, involving multiple areas in 
both lungs. Yet at autopsy, several months after stopping azathioprine and 
prednisone, there was no trace of tumor. 
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The relative ability O'f neQplastic tissue to' selectively thrive as part Qf a 
cO'mposite homograft O'nce it has achieved a fQothold was also dramatically 
illustrated by a case of Tunner et al. (1971). A kidney cQntaining a hyper-
nephroma was rejected to' the point O'f no functiO'n in 12 weeks in spite O'f 
immunO'suppressiO'n. Three weeks later, after an unsuccessful secO'nd trans-
plantation, the recipient died. At autopsy, the neO'plastic tissue Qf the trans-
plant was found to' be free Qf histO'pathologic signs of rejectiO'n and to' be 
vigQrously invading adjacent structures. In cO'ntrast, the nO'n-cancerous part 
Qf the kidney had numerous and severe findings of rejectiQn. CO'nceivably, 
the 'escape' from contrQl O'f the neoplastic cells at the same time as rejectiO'n 
O'f normal tissue from the same dO'nQr could be cO'ntributed to' by the lQSS 
O'f histQcompatibility antigens in malignant cells (Weiler 1959, Tyler 1960). 
IMMUNOSUPPRESSION AND METASTASES 
Some General Principles 
Thus far, we have cO'mmented upon twO' kinds O'f clinical O'bservations in 
immunosuppressed patients, first cO'ncerning de novo malignancies and then 
transplanted ones, that are unequivocal SUPPQrt of the hYPQthesis of im-
munO'lO'gic surveillance. A third situatiQn, and Qne about which the existing 
evidence is nO't so firm, will nO'w be cO'nsidered as it has alsO' been studied 
in the Qrgan transplantatiQn environment. 
As annO'tated earlier, acceleratiO'n O'f metastases has been reported in 
animals treated with prednisone, ALG, and azathioprine. The same thing 
has been described after the perfO'rmance O'f splenectO'my (Alford et al. 
1966). CO'nsequently, there is ample reasO'n to' suspect that effective im-
munosuppressiO'n in man might, by the further erQsiO'n O'f an already crum-
bling surveillance, facilitate the grQwth Qr spread Qf an established neoplasm 
Qr O'f residual tumQr after incO'mplete destructiQn O'r extirpatiO'n. The theught 
is werth centemplating even by thO'se in erdinary clinical practice since SQme 
ef the most widely used cancer chemetherapeutic agents have indisputable 
immunosuppressive qualities in addition to' their tumQrocidal Qnes and might, 
therefQre, theQretically be capable under seme circumstances ef an effect 
eppesite to' that which is desired. 
TO' demenstrate the cO'mbinatiO'n ef tumerocidal plus immunosuppressive 
effects, the fQur examples Qf azathiQprine, nitrQgen mustard, methetrexate, 
and cyclephosphamide will suffice altheugh numerous Qthers CQuid be cited. 
Cyclephesphamide is a particularly interesting drug since it has been Qne 
ef the most extensively evaluated and highly thQught Qf anticancer agents 
ever released fQr clinical trial; that it can inhibit the grewth Qf seme kinds 
Transplant. Rev. (1971) 7 
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of tumors is beyond reasonable doubt. However, it is also an immunosup-
pressant of such potency that it threatens to replace azathioprine as the 
cornerstone of therapy in our organ transplantation program (Starzl et ai. 
1971). Because of the latter fact, more attention will have to be paid in 
the future to the possible adverse effects just alluded to of which drugs like 
cyclophosphamide are not yet suspect, including the promotion of de novo 
or transplanted tumors as already described or even the fostering of meta-
stases from certain types of primaries as will be discussed below. 
Liver Transplantation For Hepatoma 
In view of the potentially self-defeating aspects just described of systematic 
immunosuppression in patients with established cancer, it will come as no 
surprise that our efforts to treat extensive hepatomas by total hepatectomy 
and liver replacement have frequently failed due to recurrence of neoplasm 
in spite of the fact that no tumor was thought to have been left (Starzl 1969, 
Starzl et al. 1970). It might be persuasively argued that the frequency and 
seriousness of the recurrences were approximately predictable from what 
is already known (Gustafson 1937, Spatt & Grayzel 1948, Berman 1959) 
Figure 5. A small hepatoma (surrounded by arrows) in a liver that was replaced at 
the age of 3 years, 10 months, because of biliary atresia . 
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68 days 
• A 
L 
94 days 
B 
Figure 6. Destruction of an orthotopic liver homograft by tumor recurrence . The 
posteroanterior and lateral liver scans were obtained with technetium. A: 68 days. 
The scan is normal. B: 94 days. The patient had become jaundiced. Hepatomegaly 
is evident. C: 101 da ys. Multiple areas of poor isotope concentration are now visible. 
D : III days. The process has continued its rapid progression . By the time of death 
one month later, the homograft was almost completely replaced with carcinoma. 
(By pennission of W. B. Saunders Co., 1969.) 
about the highly unfavorable natural history of primary hepatic malignan-
cies. The alternative opinion that growth of residual microscopic deposits 
was actually enhanced by immunosuppression is equally unprovable. Both 
views could be consistent with the actual observations, which were as fol-
lows. 
The preoperative diagnosis of hepatoma was the reason for proceeding 
with liver transplantation in 12 patients at our institution. Six of these 12 
recipients had underlying cirrhosis of the Laennec, postnecrotic, and biliary 
varieties in 3, 2, and 1 instances, respectively . The biliary cirrhosis was in 
a 10-year-old child with biliary atresia . An additional unsuspected small 
• 
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c 
101 days 
III days 
D 
hepatoma (Figure 5) was found in the liver of another child treated for intra-
hepatic biliary atresia, making a total of 13 cases available for observation. 
Seven of the 12 patients with prospectively diagnosed primary cancer 
of the liver died early, from 6Y2 to 39 days after orthotopic hepatic homo-
transplantation. Five of these cases were amongst the first 7 in our ex-
perience; an important contributory cause of failure was the use of l.ivers 
that had been badly damaged by ischemia. The other 2 patients who were 
treated at a later time died of technical accidents with subphrenic abscesses 
and bile peritonitis, respectively. At autopsy, an exhaustive search was made 
to determine whether any metastases had been missed with the preoperative 
survey and the operative examination. No residual tumor was found in 6 
of the 7 recipients. In the other patient, who died 7 Y2 days after trans-
plantation, there had been previously unsuspected spread to a lumbar ver-
tebra. 
The other 6 recipients including the one with an incidental hepatoma lived 
through the immediate effects of the operation and became available for 
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longer-term studies. In all 6, hepatic cell carcinoma (hepatoma) was the 
histologic diagnosis. Five of the patients died 76, 143, 339, 400, and 432 
days after operation (Table V). Recurrent neoplasm was responsible for the 
death of 4 of the recipients. The fifth (OT 26) died of other causes but 
had developed a metastasis to the left lung. The most common sites of 
spread (Table V) were the lungs and the liver homografts (4 examples each). 
In some cases, the rate of secondary growth was amazingly rapid (Figure 6). 
The only patient in our series with hepatoma still surviving is the 4-year-
old girl with biliary atresia whose tumor was not known in advance to be 
present (Figure 5). In this case sera were examined for the presence of the 
fetoprotein (Alpert et al. 1971) which when found essentially always sig-
nifies the diagnosis of hepatoma (Alpert et al. 1968). Fetoglobulin was found 
in the preoperative sample. After transplantation, the abnormal protein per-
sisted for more than 5 months, but in diminishing quantities until it finally 
disappeared. The child is in excellent condition 18 months postoperative and 
apparently has been cured of the hepatoma. A probable cure of hepatoma 
in one of CaIne's patients has also been reported (Evans & Lehmann 1971). 
However, both CaIne and Fortner et al. (1970) have also encountered meta-
stases in patients with an otherwise successful liver transplantation. 
Because of the high rate of recurrent carcinoma in our own experience 
and in that of others, it has become our policy in cases of hepatoma to 
consider liver replacement only under the most exceptional circumstances. 
Renal Transplantation For Cancer 
As already emphasized, the role, if any, of immunosuppression in promoting 
the metastases described in the preceding section after liver transplantation 
could not be proved. 
The results of renal transplantation at the same time or at varying times 
after nephrectomy for Wilm's tumor or renal cell carcinoma have been 
equally inconclusive. In 9 bona fide cases collected from other centers (Penn 
1970), mostly from personal communication, there were 5 patients who 
developed metastases. Two more recipients died too soon after transplan-
tation to provide meaningful follow-up, but the final two lived long enough 
to be considered cured of their original cancers. 
THE ENDOWMENT OF IMMUNOLOGIC SURVEILLANCE 
It was not long after the notion of immunologic surveillance became widely 
known that efforts were made to exploit the concept for the treatment of 
cancer. The following remarks will be concerned with our own reflections 
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about the matter (Marchioro et al. 1964, Starzl 1964a, Starzl et al. 1965) 
and not with an attempt to review even a fraction of the enormous literature 
bearing on this possibility. Nevertheless, it is worth mentioning that the idea 
of endowing a new surveillance apparatus has been a major theme in the 
clinical work of Dr. Georg;; Mathe (1971) and Dr. GCO'rge Moore (1970) 
during much of the past decade. 
The rationale of all such proposals can best be appreciated by directly 
quoting Thomas' (1959) view of surveillance as he expressed it in his dis-
cussion of a paper by Sir Peter Medawar given at a symposium on hyper-
sensitive states in New York City in 1957. In commenting on the possible 
biologic significance of homograft rejection, he speculated: 
. .. (Among) functions that leap to the mind ... One has to do with the universal 
requirement of multicell ular organisms to preserve uniformity of cell type and to 
prevent mutant cells from colonizing and flourishing. This may be a real hazard, 
if we can judge from the readiness of bacterial cells to undergo mutation, or the 
weird cell forms of malignant appearance that develop and multiply, and outgrow 
and replace, normal epithelial cells in tissue cultures. Perhaps, in short, the phenom-
enon of homograft rejection will turn out to represent a primary mechanism for na-
tural defense against neoplasia. The numerous analogies between this reaction and 
the immunologically induced destruction of experimental tumors (or their prolonged 
preservation after flooding an animal with tumor antigen) are consistent with this 
line of speculation. 
If this were indeed the case, one might expect that a defect in the mechanism of 
delayed-type hypersensitivity would result in special susceptibility to neoplasia ... 
It is not difficult to recognize the following thought, written in 1963 (Starzl 
1964a), to be a corollary of Thomas' statement: 
Immunology may play a significant role in future cancer therapy ... One unexplored 
approach may be to change the cancer victim's immunologic pattern by replacing it 
with the reticuloendothelial (lymphoreticular) system of a donor. Since cancer cannot 
ordinarily be transplanted from one patient to another, there is reason to believe that 
complete alteration of the immune potential of the patient might cause the tumor to 
be rejected. Such an approach awaits perfection of techniques of homologous tissue 
transplantation. In simplified terms, it would be necessary to destroy the patients 
reticuloendothelial system, and replace it with donated bone marrow or spleen, and 
perhaps other reticuloendothelial components. 
Early Efforts at Promoting a Graft- Versus- Tumor Reaction With Spleen Grafts 
In February, April, and May 1963, 4 patients were given whole organ spleen 
homografts which had been sensitized against the tumor tissue of the even-
tual recipient by the scheme shown in Figure 7 (Marchioro et at. 1964, 
Starzl et al. 1965). In essence, fragments of the carcinoma were removed, 
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killed by emulsification, mixed with Freund's adjuvant, and injected sub-
cutaneously into the next cancer victim, who 2 to 8 weeks later became 
the donor of a 'preinstructed' spleen. The splenic transplantations were to 
the extra peritoneal space of the recipients' iliac fossa, anastomosing the 
splenic vessels to the hypogastric artery and the external iliac vein. 
The types of malignancies were alveolar cell carcinoma of the lung and 
carcinomas of the stomach (2 cases), and kidney. Postoperative immuno-
suppression was given with azathioprine and prednisone. One of the re-
cipients developed an acute hemolytic anemia, probably because of a breach 
of red cell group compatibility (tissue transfer from Group 0 to A). This 
patient ruptured his new spleen and died 10 days postoperatively of as-
piration while on the way to the operating room. The other 3 recipients 
died of metastases after 2, 3, and 21 months. By the time of autopsy, the 
splenic homografts had involuted. 
The two organs that had been in residence for 2 and 3 months weighed 
400 and 240 grams, respectively. They were very firm. Microscopically, 
broad bands of fibrous connective tissue and/or necrotic areas replaced large 
amounts of parenchyma (Figure 8). Scattered throughout were small patches 
Figure 7. Experimental procedure in patients with disseminated malignancies who were 
treated with splenic homotransplantation. Note that the donor is sensitized with the 
recipient's tumor in each case. (By permission of Sth. med. J. 58, 131, 1965.) 
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of hemorrhage and some aggregates of lymphocytes. White pulp was not 
identified. The patient who lived for 21 months had immunosuppression 
stopped 9 months post-transplantation. By the time of death from carcinoma-
tosis, one year later, the residual spleen graft had become a first-sized mass 
of connective tissue; the splenic artery and vein were thrombosed. 
The natural history of the malignancies was not altered in any obvious 
way. In retrospect, it must be conceded that the trials could net be properly 
evaluated since rejection of the homografts was not prevented in any of 
the three longest surviving cases. The two homografts retrieved at autopsy 
after 2 and 3 months retained gross characteristics of spleen, but micro-
scopic study showed architectural disruptions so extensive that it is difficult 
to conceive of functional integrity of the organs in terms of a chronic graft-
versus-tumor reaction. 
The use of whole spleen homotransplantation for the treatment of ma-
lignant neoplasm has not been described by any other group. However, 
Woodruff attempted the intravenous infusion of spleen cell suspensions 
(Woodruff & Nolan 1963). Apparently the course of the widespread tu-
Figure 8 . Photomicrograph of splenic homograft obtained at autopsy 2 
operatively. Note the widespread necrosis with complete loss of architecture (hema-
toxylin and eosin, x 80). (By permission of Ann. N.Y . Acad. Sci. 120, 626. 1964.) 
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mms in his patients was not substantially affected, inasmuch as there have 
been no follow-ups to the mildly optimistic preliminary communication. 
Bone Marrow and Graft-Versus-Tumor Reactions 
The Barrier of the Graft- Versus-Host Reaction. There are two sequential 
problems that must be solved before the transplantation of immunocom-
petent tissue can be evaluated for the treatment of human malignancy. The 
first, and one toward which major progress has been made, is to prevent 
rejection of the graft by the host. The second is to prevent fatal rejection 
of the host by the graft while at the same time retaining enough graft-versus-
host activity to permit killing of the neoplasm. 
Speculation about a differential lethal effect upon a tumor in combination 
with a sparing of normal recipient tissues and O'rgans may require the spe-
cial kind of optimism that strays beyond logic. However, the potential role 
of T-antigens in promoting such a specific vulnerability of neoplastic cells 
was discussed earlier. In addition, the possibility cannO't be excluded that 
neoplastic tissue might present a spectacularly susceptible target to' a graft-
versus-host reaction for strictly non-immunologic reasons. The relative ease 
with which tumor tissue can be damaged is the essential reason fO'r the 
success of many other kinds of anticancer treatment including irradiation. 
For the moment, the question of a differential graft-versus-host reaction 
must remain moot since the simple fact is that the satisfactory test con-
ditions to' provide an answer have not yet been fulfilled. A few successful 
bDne marrow transplantations have been performed, but essentially always 
between siblings with identity of the major histocompatibility (HL-A) sys-
tem (Bach et al. 1968, Gatti et al. 1968, Mathe et al. 1970, Santos et at. 
1970, Speck et at. 1970), and even then usually for the indication of one 
of the immune deficiency diseases. In the event of a compatibility so perfect 
that nO' adverse cDnsequences are seen, much of the therapeutic potential 
offered by a vigorous graft-versus-host reactiDn would be predicted to be 
lost. Yet, with all other kinds of donors, including those from within the 
family, the outcome has been a fatal graft-versus-host reaction. 
It is probable that the exceedingly limited reference in which bone marrow 
transplantation has had any chance at all of success is partly due to the 
kind of immunosuppression that has been employed. In the first trials for 
patients not suffering from spontaneous immunologic deficiency, total body 
irradiation was used (Van Bekkum & DeVries 1967, Mathe et al. 1971). 
More recently, cyclophosphamide, other drugs, Dr antilymphocyte globulin 
(ALG) have been employed. With all these agents, the principle has been 
to cripple the recipient immunologically in advance of grafting. For ex-
ample, cyclophDsphamide which is presently enjoying a wave of popularity 
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has been given for a few days before the marrow infusion in the prodigious 
daily quantities of 45-200 mg/kg (Bortin et aT. 1971, Santos 1971). After 
transplantation, little or no therapy has been provided. What has been asked 
in such cases is the almost instant induction of tolerance in the recipient 
in order to make possible graft acceptance but with the added proviso that 
there be good enough histocompatibility to avoid the fatal graft-versus-host 
reaction that would otherwise ensue without follow-up treatment. 
To achieve more than isolated successes after bone marrow transplan-
tation even with the highly favorable double haplotype identical sibling 
combinations, it would seem reasonable to give less extreme but more pro-
tracted treatment such as that used after whole organ transplantation. When 
this is done after transplantation of kidneys, livers, and hearts, a charac-
teristic cycle transpires during which the host-graft relationship is altered 
and after which the degree of immunosuppression required to retain the 
graft is reduced in successful cases (Starzl 1964b. 1969). This kind of im-
munosuppressive regimen, which would simultaneously treat the immuno-
competent cells of the host as well as those of the graft with combinations 
of agents, has not been evaluated for bone marrow transplantation. 
A Justification for Hope. Earlier, a possible element of circular reasoning 
was mentioned in any scheme to exploit controlled graft-versus-host reac-
tions to treat human tumors. The circle begins with the firm evidence that 
immunosuppression emasculates surveillance and, therefore, is a factor in 
oncogenesis. It could close with the acknowledgment that effective and prob-
ably chronic immunosuppression must be used to prevent and/or combat 
complicating and lethal graft-versus-host reactions that must be dealt with 
if bone marrow is to be given to patients in the hope of suppressing neo-
plasia. It is possible that the appropriate juggling of all the biological and 
therapeutic factors to achieve the desired effect upon neoplastic growth will 
prove to be an impracticality. 
If so, an important prospect for therapy will be lost since there is con-
siderable evidence, recently summarized by Santos (1971), that bone marrow 
grafts can have a profoundly inhibitory effect upon malignancies. In more 
than a dozen cases, patients have had remissions of leukemia lasting from 
several weeks to as long as 8 months after bone marrow transplantation. 
Moreover, other kinds of malignancy have been noted to regress or dis-
appear for shorter intervals in animals which died from graft-versus-host 
reaction, infection, or other causes. As an example in dogs, Epstein et al. 
(1971) of Seattle recently reported tumor involution in a series of sarcomas 
and one anaplastic carcinoma. Eight of their animals lived for more than a 
week after succesful bone marrow transplantation with maximum survival of 
60 days. None of these dogs had any residual tumor at the time of its death. 
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SUMMARY 
The hypothesis that immunologic surveillance is nature's way of preventing 
and controlling malignant neoplasia has received three kinds of support 
from clinical observations after organ transplantation under continuous im-
munosuppression. First, de novo epithelial or mesenchymal tumors have 
been observed throughout the world in 57 chronic survivors of whole organ 
transplantation. including 15 of our own patients, for an incidence far ex-
ceeding that in a normal population. Second, malignant tumors have been 
accidently transplanted along with renal homografts, have become auton-
omous and invasive once well established, but have been rejected in two 
instances after stopping immunosuppression. Finally and least conclusively, 
the environment fOor metastatic growth of residual tumOor may have been 
made more permissive after total hepatectomy or nephrectomy followed by 
liver or kidney transplantation. 
If the surveillance hypothesis is accepted and if it is conceded that clini-
cally evident cancer represents a failure of a fundamental biolOogic control 
system, it becOomes natural to cOonsider means of conferring new immuno-
logic defenses upon patients with uncontrolled malignancy. This has been 
attempted by us with whole organ spleen transplantation and by others with 
transplantatiOon of bone marrow or other immunocompetent tissue. Long-
term cures have not been obtained, but there have been SOome indications 
of an antitumor effect of such grafts. Further testing of this approach will 
require better regulation of the consequences of graft-versus-host reactions, 
possibly by applying some principles Oof immunosuppression that have been 
well standardized with the transplantatiOon of whole Oorgans. 
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